GlassScriptPhysician profile
Sarah E Madden
NPI 1235511619
$2,391.45
in general payments reported to CMS, 2019-2025
26 companies · $779 in 2025
The $779 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.61 · 2022: $597 · 2023: $572 · 2024: $370 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412 · Travel and Lodging: $295 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.63 |
| Travel and Lodging | $295.18 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $310.21 | 2022-2025 | Farxiga, Evusheld |
| Boston Scientific Corporation | $295.18 | 2025 | Axonics |
| Calliditas Therapeutics US INC. | $289.35 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $207.37 | 2022-2025 | Jynarque |
| Akebia Therapeutics INC | $175.13 | 2022-2023 | Auryxia |
| Amgen INC. | $126.83 | 2021-2025 | Tavneos, Parsabiv |
| Aurinia Pharma U.S., INC. | $114.23 | 2022-2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $92.43 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $91.74 | 2023-2024 | Terlivaz, Acthar |
| Glaxosmithkline, LLC. | $86.67 | 2023-2024 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $80.77 | 2022-2025 | |
| Vifor Pharma, INC. | $80.36 | 2021-2023 | Veltassa |
| Genzyme Corporation | $77.60 | 2022-2025 | |
| Abbvie INC. | $58.42 | 2021-2023 | |
| Scpharmaceuticals INC. | $44.91 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.49 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $34.93 | 2022-2025 | Injectafer |
| Recor Medical INC | $31.42 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ardelyx, INC. | $26.12 | 2025 | Ibsrela |
| Renalytix Ai, INC. | $19.97 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Cvrx, INC. | $19.57 | 2024 | Barostim Neo System |
| Alexion Pharmaceuticals, INC. | $17.65 | 2024 | Ultomiris |
| Ani Pharmaceuticals, INC. | $17.41 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $17.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.74 | 2024 | Keveyis |
| Fresenius USA Marketing, INC. | $15.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Madden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.